Vaccine Responses in Patients With B Cell Malignancies

Inclusion Criteria

• •Diagnosis of CLL, FL, MCL, MZL, NHL NOS or WM
• •Must fulfil one of the following criteria to be enrolled in one study arm per vaccine received:
• •1. Patients with CLL AND one of the following:
• •i. Arm 1: Must be treatment naive (no prior cancer directed therapy)
• •ii. Arm 2: Patients that have received prior cancer directed therapy and are currently not receiving active treatment
• •iii. Arm 3: Must be receiving treatment with a BTKi. This arm is not available to patients receiving the HEPLISAV-B vaccine
• •iv. Arm 4: Must be receiving treatment with a BTKi for \>= 6 months prior to vaccination and be willing to hold their treatment for up to 7 weeks around the time of each vaccination. This arm is not available to patients who have had a prior episode of disease flare during periods of drug hold, or for patients with CLL that is actively progressing.
• •v. Arm 5: Must be receiving treatment with a BCL-2 inhibitor
• •Or
• •2. Patients with FL, MCL, MZL, NHL NOS or WM AND one of the following:
• •i. Arm 1: Must currently not be receiving active treatment (treatment na(SqrRoot) ve or previously treated)
• •ii. Arm 2: Must be receiving treatment with targeted therapies (e.g. BTKi, BCL-2 inhibitors, PI3K inhibitors, immunomodulatory agents, proteasome inhibitors)
• •If prior exposure to Hepatitis-B vaccination, must have documentation of negative serologic response
• •Age \>= 18 years
• •Able to comprehend the investigational nature of the protocol and provide informed consent